Lilly 4Q Revenues: $6.4 billion (+5%) 4Q Earnings: $1.1 billion (loss of $1.7 billion 4Q17) FY Revenues: $24.6 billion (+7%) FY Earnings: $3.2 billion (loss of $204 million FY17) Comments: Revenue in the U.S. increased 7% to $3.7 billion, driven by increased volume, partially offset by lower realized prices, primarily in the diabetes portfolio. Growth was driven by newer products, including Trulicity, Taltz and Basaglar, partially offset by decreased volume for products that have lost exclu...